The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Proteomic cancer biomarkers from discovery to approval: it’s worth the effort
Open accessAbstract
The current landscape of cancer biomarkers is changing rapidly, with new and exciting developments. With the advances of proteomic technologies, many potential cancer biomarkers have been discovered. However, the number of new cancer biomarkers cleared or approved by the US FDA is rather limited. Although technological advances are important, clearly defining intended use, good study design and appropriate patient specimens are critical for the success of FDA approval. While obtaining FDA clearance/approval for newly developed and clinically useful cancer biomarkers has been slow, the reward for patient care could be enormous.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zhang, Z., Bast, R. C., Yu, Y., Li, J., Sokoll, L. J., Rai, A. J., Rosenzweig, J. M., Cameron, B., Wang, Y. Y., Meng, X.-Y., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0746 · Cited by 929
Self-citationThe HE4 (WFDC2) protein is a biomarker for ovarian carcinoma.
Hellström, I., Raycraft, J., Hayden-Ledbetter, M. S., Ledbetter, J. A., Schummer, M., McIntosh, M. W., Drescher, C. W., Urban, N. D., & Hellström, K. E. (2003) · PubMed · Cited by 711
A precursor form of PSA (pPSA) is a component of the free PSA in prostate cancer serum
Mikolajczyk, S. D., Grauer, L. S., Millar, L. S., et al. (1997) · Urology · doi:10.1016/s0090-4295(97)00449-4 · Cited by 167
Zhang, Z. (2012) · PubMed · Cited by 51
Flagged first, then by citations
Research works printed but not linked: 3
- Hellström I, 2003, Cancer Res, 63, 3695
- Wang M, 1979, Invest Urol, 17, 159
- Zhang Z, 2012, Rev Obstet Gynecol, 5, 35
Cited by
Sorted by citations
Matsuoka, T., & Yashiro, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25115880 · Cited by 83
“The developments in knowledge and technologies of high-throughput mass spectroscopy (MS) provoke the identification of effective biomarkers for GC [47].”
Background
Metadata
- Authors
- Li, D., & Chan, D. W.
- Affiliations
- University of Minnesota (US)
- Johns Hopkins University (US)
- Corresponding author
- Li, Danni
- Venue
- Expert Review of Proteomics
- Publisher
- Informa UK Limited
- Published
- 2014-03-20
- Volume
- 11
- Issue
- 2
- Pages
- 135-136
- ISSN
- 1478-9450 (ISSN-L)
- 1744-8387
- PMC
- PMC4079106
- OpenAlex
- W2143199634
- Cited by
- 54
- References
- 4
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 6 · 2023: 2 · 2022: 6 · 2021: 4 · 2020: 3 · 2019: 6 · 2018: 7 · 2017: 4 · 2016: 8 · 2015: 2 · 2014: 1
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Expert Review of Proteomics (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (R13CA177252, U24CA160036, U24CA115102)
- Topics
- Physical Sciences › Chemistry › Spectroscopy › Advanced Proteomics Techniques and Applications
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Advanced Biosensing Techniques and Applications
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- tumor markers, proteomics, biomarker discovery, FDA approval, regulatory approval, intended use, research design, clinical translation
- MeSH terms
- Humans, Neoplasms, Prognosis, Biomarkers, Tumor, Proteome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
